Cell Biology Engineering Treatment 
Chemical Biology and Drug Design
JULY 26, 2023
Exosome engineering can be conducted through surface and content modification of biological exosomes. In preisolation method, parental cells are stimulated to express some special genes like lncRNAs, miRNAs, and receptors to have the capacity to bind to the target cells and deliver their content.
Drug Target Review
JUNE 5, 2023
ZW191 is an antibody-drug conjugate (ADC) that is engineered to target folate receptor-⍺ (FR⍺), a protein that has limited expression in normal tissues but is often elevated on a variety of tumours including epithelial ovarian, endometrial, triple negative breast and lung adenocarcinoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
OCTOBER 16, 2023
As we explore translatability, technological advancements and the integration of artificial intelligence (AI), we envision the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalised clinical treatments, ultimately reducing costs and improving patient outcomes.
Drug Target Review
NOVEMBER 17, 2023
Only three of the CAR-NK studies were for the treatment of solid tumours. The non-CAR-NK studies showed very good safety data when compared to neurological and cytokine storm responses reported for CAR-T cell trials. Three patients were treated with 2-6 doses of 2×10 7 to 2×10 9 cells.
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. When I began my PhD I completely switched my focus, and I haven’t looked back,” said Manguso.
Drug Target Review
JULY 13, 2023
Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development.
Drug Target Review
JUNE 7, 2024
Unlike existing immunotherapies that are designed to “remove the brakes” from exhausted, pre-existing tumour-specific T cells, the ImmTAC platform can redirect any T cell in the patient’s body to recognise and kill tumour cells expressing the target of interest the ImmTAC was engineered for.
Expert insights. Personalized for you.
100 
Let's personalize your content